Small Molecule-Drug Conjugates: Getting Small to Enhance Targeting

Time: 2:30 pm
day: Day Two

Details:

  • Understanding how ADC products are limited by their slow and inefficient accumulation in solid tumours. Small Molecule-Drug Conjugates have been recently proposed as an alternative approach to deliver potent cytotoxic compounds to the neoplastic site and to solid metastatic lesions
  • Acetazolamide is a small organic compound that exhibits a high binding affinity to the tumour-associated antigen Carbonic Anhydrase IX (CAIX), a marker of Renal Cell Carcinoma and of hypoxic tumours. We compared acetazolamide-based SMDC products to anti-CAIX ADCs for their ability to reach tumours in vivo and for their anti-tumor performance
  • Analysing recent clinical trial data that have confirmed the efficient accumulation of an acetazolamide-based radiotracer (PHC102) to solid tumours and metastatic lesions in Renal Cell Carcinoma patients

Speakers: